Cargando…

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Prunas, Ottavia, Warren, Joshua L., Crawford, Forrest W., Gazit, Sivan, Patalon, Tal, Weinberger, Daniel M., Pitzer, Virginia E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722617/
https://www.ncbi.nlm.nih.gov/pubmed/34981074
http://dx.doi.org/10.1101/2021.07.13.21260393
Descripción
Sumario:The individual-level effectiveness of vaccines against clinical disease caused by SARS-CoV-2 is well-established. However, few studies have directly examined the effect of COVID-19 vaccines on transmission. We quantified the effectiveness of vaccination with BNT162b2 (Pfizer-BioNTech mRNA-based vaccine) against household transmission of SARS-CoV-2 in Israel. We fit two time-to-event models – a mechanistic transmission model and a regression model – to estimate vaccine effectiveness against susceptibility to infection and infectiousness given infection in household settings. Vaccine effectiveness against susceptibility to infection was 80–88%. For breakthrough infections among vaccinated individuals, the vaccine effectiveness against infectiousness was 41–79%. The overall vaccine effectiveness against transmission was 88.5%. Vaccination provides substantial protection against susceptibility to infection and slightly lower protection against infectiousness given infection, thereby reducing transmission of SARS-CoV-2 to household contacts.